Anti-tumor necrosis factor-a for the treatment of steroid-refractory acute graft-versus-host disease

Anti-tumor necrosis factor-a for the treatment of steroid-refractory acute graft-versus-host disease

Allogeneic stem cell transplantation has been increasingly performed for a variety of hematologic diseases. Clinically significant acute graft-versus-host disease (GVHD) occurs in 9 to 50% of patients who receive allogeneic grafts, resulting in high morbidity and mortality. There is no standard ther...

Full description

Bibliographic Details
Main Authors: M.C. Nogueira, A.M. Azevedo, S.C.M. Pereira, J.L. Ferreira, D. Lerner, A.M.G. Lobo, R.C.B.S. Tavares, D.G. Tabak, N. Lorenzi, I.Z. Renault, L.F.S. Bouzas
Format: Article
Language:English
Published: Associação Brasileira de Divulgação Científica 2007-12-01
Series:Brazilian Journal of Medical and Biological Research
Subjects:
Infliximab
Graft-versus-host disease
Hematopoietic stem cell transplantation
Online Access:http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2007001200005

Internet

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2007001200005

Similar Items